|
|
|
      |
 | |
|
What's New OMNIA BIOLOGICS AND PROLONG SIGN PRODUCTION SERVICES AGREEMENT Omnia Biologics (Omnia) is a contract manufacturer focused on clinical trials material manufacture of innovative biopharmaceuticals. Prolong is a biopharmaceutical company whose core technology is an FDA approved delivery system for protein-based biopharmaceuticals, known as PEGylation. This process involves the chemical attachment of polyethylene glycol ("PEG") to a therapeutic protein. The result is a product that has significantly improved therapeutic properties, with reduced side effects that affords better patient compliance. Prolong is developing long-acting biopharmaceuticals through its own research and by collaboration. "Dr. Abuchowski's record of success in both the academic and commercial development of PEG technology is legend in our business." Sami Cardak, Director of Manufacturing, Omnia Biologics, Inc commented on the deal. "Prolong's strategy to make PEG technology more widely available to not only extend patent life of current drugs but also to improve the bioavailability of new classes of drugs will be a great benefit to the patients these drugs will help. We are proud that Prolong chose Omnia to assist them in this important work." About Omnia Biologics: (www.omniabiologics.com) Omnia offers services in the areas of process development, GMP manufacture, and fill-finish for preclinical and Phase I clinical programs for therapeutics that do not have effective or known manufacturing protocols. These include vaccines, autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world. ### CONTACT: Omnia Biologics, Inc. |